Fox Run Management L.L.C. Acquires 32,579 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Fox Run Management L.L.C. increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 199.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,950 shares of the biopharmaceutical company’s stock after buying an additional 32,579 shares during the period. Fox Run Management L.L.C. owned 0.08% of Sage Therapeutics worth $266,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Quest Partners LLC boosted its holdings in shares of Sage Therapeutics by 56.3% in the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,618 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Sage Therapeutics during the 3rd quarter worth about $473,000. Intech Investment Management LLC bought a new position in Sage Therapeutics in the 3rd quarter worth about $146,000. Charles Schwab Investment Management Inc. grew its holdings in Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after buying an additional 43,617 shares in the last quarter. Finally, Algert Global LLC increased its position in shares of Sage Therapeutics by 120.6% during the third quarter. Algert Global LLC now owns 143,034 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 78,190 shares during the period. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Up 0.7 %

NASDAQ SAGE opened at $8.66 on Friday. The company has a 50-day simple moving average of $7.45 and a two-hundred day simple moving average of $6.73. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $19.34. The firm has a market cap of $532.43 million, a price-to-earnings ratio of -1.31 and a beta of 0.82.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Equities analysts expect that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SAGE has been the subject of a number of analyst reports. Stifel Nicolaus cut their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research report on Monday, December 16th. HC Wainwright restated a “neutral” rating and set a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Bank of America initiated coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, Piper Sandler decreased their target price on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.